AU2004205270B2 - Colorectal cancer prognostics - Google Patents
Colorectal cancer prognostics Download PDFInfo
- Publication number
- AU2004205270B2 AU2004205270B2 AU2004205270A AU2004205270A AU2004205270B2 AU 2004205270 B2 AU2004205270 B2 AU 2004205270B2 AU 2004205270 A AU2004205270 A AU 2004205270A AU 2004205270 A AU2004205270 A AU 2004205270A AU 2004205270 B2 AU2004205270 B2 AU 2004205270B2
- Authority
- AU
- Australia
- Prior art keywords
- dna
- human
- equals
- misc feature
- hume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010009944 Colon cancer Diseases 0.000 title claims description 27
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 133
- 230000014509 gene expression Effects 0.000 claims description 96
- 241000282414 Homo sapiens Species 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 37
- 238000004458 analytical method Methods 0.000 claims description 21
- 238000004393 prognosis Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000012567 pattern recognition method Methods 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims 2
- 235000015250 liver sausages Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 239000000523 sample Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000012549 training Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 101710196881 Cadherin-17 Proteins 0.000 description 6
- 102100024152 Cadherin-17 Human genes 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 5
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101150029062 15 gene Proteins 0.000 description 3
- 101150029857 23 gene Proteins 0.000 description 3
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 3
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 3
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 3
- 102100024573 Macrophage-capping protein Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 2
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100039699 G antigen 4 Human genes 0.000 description 2
- 101710092263 G antigen 4 Proteins 0.000 description 2
- 102100039831 G patch domain-containing protein 3 Human genes 0.000 description 2
- 101001034106 Homo sapiens G patch domain-containing protein 3 Proteins 0.000 description 2
- 101000590492 Homo sapiens Nuclear fragile X mental retardation-interacting protein 1 Proteins 0.000 description 2
- 101000735566 Homo sapiens Protein-arginine deiminase type-4 Proteins 0.000 description 2
- 101000668416 Homo sapiens Regulator of chromosome condensation Proteins 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100032428 Nuclear fragile X mental retardation-interacting protein 1 Human genes 0.000 description 2
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 2
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 108700021031 cdc Genes Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 108700020469 14-3-3 Proteins 0.000 description 1
- 102100024682 14-3-3 protein eta Human genes 0.000 description 1
- 101150092328 22 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 102100032296 A disintegrin and metalloproteinase with thrombospondin motifs 12 Human genes 0.000 description 1
- 108091005671 ADAMTS12 Proteins 0.000 description 1
- 102100026425 Adhesion G protein-coupled receptor E3 Human genes 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 102100035356 Cadherin-related family member 5 Human genes 0.000 description 1
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 1
- 108010028326 Calbindin 2 Proteins 0.000 description 1
- 102100021849 Calretinin Human genes 0.000 description 1
- 102100033377 Carbohydrate sulfotransferase 15 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101150096994 Cdx1 gene Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101710170295 Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101800000620 Disintegrin-like Proteins 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710083182 Fatty acid-binding protein 1 Proteins 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 description 1
- 101000718235 Homo sapiens Adhesion G protein-coupled receptor E3 Proteins 0.000 description 1
- 101000737803 Homo sapiens Cadherin-related family member 5 Proteins 0.000 description 1
- 101000943842 Homo sapiens Carbohydrate sulfotransferase 15 Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101000911317 Homo sapiens Fatty acid-binding protein, liver Proteins 0.000 description 1
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 1
- 101001049831 Homo sapiens Potassium channel subfamily K member 4 Proteins 0.000 description 1
- 101710116716 Krueppel-like factor 5 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 102100035192 Laforin Human genes 0.000 description 1
- 101710192391 Laforin Proteins 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100023205 Potassium channel subfamily K member 4 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 108010011677 glyoxylate aminotransferase Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008203227A AU2008203227B2 (en) | 2003-08-28 | 2008-07-18 | Colorectal cancer prognostics |
| AU2008203226A AU2008203226B2 (en) | 2003-08-28 | 2008-07-18 | Colorectal cancer prognostics |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/651,237 US20050048494A1 (en) | 2003-08-28 | 2003-08-28 | Colorectal cancer prognostics |
| US10/651,237 | 2003-08-28 | ||
| US10/782,413 | 2004-02-19 | ||
| US10/782,413 US20060063157A9 (en) | 2003-08-28 | 2004-02-19 | Colorectal cancer prognostics |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008203227A Division AU2008203227B2 (en) | 2003-08-28 | 2008-07-18 | Colorectal cancer prognostics |
| AU2008203226A Division AU2008203226B2 (en) | 2003-08-28 | 2008-07-18 | Colorectal cancer prognostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004205270A1 AU2004205270A1 (en) | 2005-03-17 |
| AU2004205270B2 true AU2004205270B2 (en) | 2009-01-22 |
Family
ID=34139107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004205270A Ceased AU2004205270B2 (en) | 2003-08-28 | 2004-08-26 | Colorectal cancer prognostics |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1512758B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4886976B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101128112B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1637151B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004205270B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0403812A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2475769C (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054508A2 (en) * | 2003-12-01 | 2005-06-16 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
| US20080058432A1 (en) * | 2006-03-03 | 2008-03-06 | Yixin Wang | Molecular assay to predict recurrence of Duke's B colon cancer |
| US20100196889A1 (en) * | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
| CN104698168A (zh) * | 2008-09-01 | 2015-06-10 | 国立大学法人名古屋大学 | 抗癌剂作用增强剂及其应用、以及癌患者预后推定用生物标记物及其应用 |
| CA2945080A1 (en) * | 2014-04-10 | 2015-10-15 | Bio-Marcare Technologies Ltd. | Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer |
| CN106367527A (zh) * | 2016-11-17 | 2017-02-01 | 苏州大学附属第二医院 | 直肠癌放化疗疗效相关靶基因的鉴定 |
| CN111560433B (zh) * | 2020-04-28 | 2022-07-19 | 福建中医药大学 | 人nufip1的用途及相关产品 |
| CN111951883A (zh) * | 2020-08-04 | 2020-11-17 | 广东省第二人民医院（广东省卫生应急医院） | 一种特征mRNA表达谱组合及结肠癌早期预测方法 |
| CN114569731B (zh) * | 2022-03-01 | 2023-05-05 | 山东大学 | 一种分子信标修饰的纳米载体及在制备抗肿瘤产品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001094629A2 (en) * | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| EP1355150A2 (en) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Panel of nucleic acid sequences for cancer diagnosis |
| WO2006085796A2 (fr) * | 2005-02-11 | 2006-08-17 | Iouri Vasilevich Martemianov | Procede pour estamper des pieces de longueur indeterminee a partir de metal en fusion |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229770B1 (en) * | 1998-10-01 | 2007-06-12 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
| JPH0856699A (ja) * | 1994-08-25 | 1996-03-05 | Tabiti Karim | 腫瘍診断及び予後 |
| CA2412223A1 (en) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| MXPA04003697A (es) * | 2001-10-31 | 2005-04-08 | Alcon Inc | Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma. |
| US20030186303A1 (en) * | 2002-03-29 | 2003-10-02 | Yixin Wang | Colorectal cancer diagnostics |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
-
2004
- 2004-08-25 CA CA2475769A patent/CA2475769C/en not_active Expired - Fee Related
- 2004-08-26 AU AU2004205270A patent/AU2004205270B2/en not_active Ceased
- 2004-08-27 KR KR1020040067990A patent/KR101128112B1/ko not_active Expired - Fee Related
- 2004-08-27 CN CN2004100832790A patent/CN1637151B/zh not_active Expired - Fee Related
- 2004-08-27 EP EP04255208A patent/EP1512758B1/en not_active Expired - Lifetime
- 2004-08-27 JP JP2004248898A patent/JP4886976B2/ja not_active Expired - Fee Related
- 2004-08-30 BR BR0403812-6A patent/BRPI0403812A/pt not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001094629A2 (en) * | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| EP1355150A2 (en) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Panel of nucleic acid sequences for cancer diagnosis |
| WO2006085796A2 (fr) * | 2005-02-11 | 2006-08-17 | Iouri Vasilevich Martemianov | Procede pour estamper des pieces de longueur indeterminee a partir de metal en fusion |
Non-Patent Citations (1)
| Title |
|---|
| Hedge et al, Cancer Research, 2001, vol 61(21), p 7792-7797 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1637151B (zh) | 2013-07-17 |
| CN1637151A (zh) | 2005-07-13 |
| KR101128112B1 (ko) | 2012-09-05 |
| EP1512758A1 (en) | 2005-03-09 |
| KR20050021916A (ko) | 2005-03-07 |
| JP2006101701A (ja) | 2006-04-20 |
| JP4886976B2 (ja) | 2012-02-29 |
| CA2475769C (en) | 2018-12-11 |
| BRPI0403812A (pt) | 2005-06-07 |
| EP1512758B1 (en) | 2012-10-17 |
| AU2004205270A1 (en) | 2005-03-17 |
| CA2475769A1 (en) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10889865B2 (en) | Thyroid tumors identified | |
| AU2017267184B2 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
| CN107941681B (zh) | 鉴定生物样品中定量细胞组成的方法 | |
| AU2013277971B2 (en) | Molecular malignancy in melanocytic lesions | |
| KR102023584B1 (ko) | 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법 | |
| RU2721130C2 (ru) | Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней | |
| RU2719194C2 (ru) | Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов | |
| US20040146907A1 (en) | Methods and compositions for detecting dysplasia | |
| KR100964193B1 (ko) | 간암 예후 마커 | |
| AU2018210695A1 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
| AU2008203226A1 (en) | Colorectal cancer prognostics | |
| CN101687050A (zh) | 用于鉴别原发起源不明的癌的起源的方法和材料 | |
| CN101258249A (zh) | 检测黑素瘤的方法和试剂 | |
| CA2403946A1 (en) | Genes expressed in foam cell differentiation | |
| KR20200123450A (ko) | 전립선암 검출 및 치료 방법 | |
| CN114127314A (zh) | 用于对乳腺癌的亚型(Subtype)进行鉴别或者分类的鉴别标志物遗传基因组、方法和套件 | |
| US20050272043A1 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| CA2666057C (en) | Genetic variations associated with tumors | |
| US20030013099A1 (en) | Genes regulated by DNA methylation in colon tumors | |
| AU2004205270B2 (en) | Colorectal cancer prognostics | |
| KR20060045950A (ko) | 혈액학적 악성종양에 대한 예후 | |
| US20020137077A1 (en) | Genes regulated in activated T cells | |
| CN100516876C (zh) | 用于诊断肾细胞癌(rcc)和其他实体瘤的方法 | |
| US20030175761A1 (en) | Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma | |
| KR20110113642A (ko) | 유방 종양의 하위분류 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |